Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BF.11.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.11.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BF.11.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
XBF.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBF.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBF.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BZ.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BZ.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BZ.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BQ.1.10.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BQ.1.10.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BQ.1.10.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BF.7.24ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.7.24NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BF.7.24NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.10ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.10NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.10NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.44ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.44NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.44NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BE.1.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BE.1.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BE.1.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BF.7.4.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.7.4.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-13240.9China
BF.7.4.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.5.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.5.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.5.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.37ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.37NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.37NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.2.57ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.2.57NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.2.57NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
CN.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
CN.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
CN.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.4.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.4.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.4.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.54ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.54NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.54NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BF.18ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.18NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BF.18NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.52ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.52NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used